Progress in Cardiovascular Diseases

Papers
(The H4-Index of Progress in Cardiovascular Diseases is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
List of recent issues242
From the editor's desk-overweight and obesity and obesity paradox in cardiovascular diseases170
Table of contents157
CTA in roadmapping post-CABG evaluation87
Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis74
Emerging tracers for cardiac imaging: Innovations and clinical implications65
Shelter from the cytokine storm: Healthy living is a vital preventative strategy in the COVID-19 era55
Chronic thrombosis of bioprostheses: Diagnosis and management54
Cover 2 (Masthead)48
List of recent issues48
Table of contents47
Cover 2 (Masthead)43
Cover 2 (Masthead)39
Estrogen and cardiovascular disease39
Use of mechanical circulatory support in high-risk percutaneous coronary interventions39
Table of contents38
Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing?38
Multimodality imaging of hypertrophic cardiomyopathy36
Updates on obesity and the obesity paradox in cardiovascular diseases35
Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials35
Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy34
Cover 2 (Masthead)34
Evidence to support health system prioritization of health behaviors in the COVID-19 era34
List of recent issues32
Editorial Board32
A meta-analysis of direct oral anticoagulants vs warfarin for left ventricular thrombus31
The weekly mortality for ischemic heart disease in the US still peaks on mondays30
Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know30
Refining cardiovascular risk assessment: The interplay of lipoprotein (a) and waist-to-hip ratio30
List of recent issues30
0.12823104858398